Geoffrey Shapiro, MD
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Geoffrey Shapiro, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:32 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03310879 · Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6Dana-Farber Cancer Institute · recruiting · Cancer · principal investigator
- Ph1NCT03170206 · Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung CancerDana-Farber Cancer Institute · completed · Lung Cancer · principal investigator
- Ph1NCT03065062 · Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsDana-Farber Cancer Institute · suspended · Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer · principal investigator
- Ph1NCT03057145 · Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid TumorsGeoffrey Shapiro, MD, PhD · completed · Solid Tumor · principal investigator
- Ph2NCT02873975 · A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair DeficiencyDana-Farber Cancer Institute · completed · Advanced Cancers · principal investigator
- Ph2NCT02656849 · BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified TumorsDana-Farber Cancer Institute · withdrawn · Solid Tumor · principal investigator
- Ph1NCT02552953 · A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced CancersCyclacel Pharmaceuticals, Inc. · completed · Cancer · principal investigator
- Ph1NCT02022982 · PALBOCICLIB + PD-0325901 for NSCLC & Solid TumorsDana-Farber Cancer Institute · completed · KRAS Mutant Non-Small Cell Lung Cancer, Solid Tumors · principal investigator
- Ph1NCT01664000 · A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid TumorsCellceutix Corporation · completed · Solid Tumors · principal investigator
- Ph1NCT01280487 · A Safety Study of Oral ZSTK474 in Patients With CancerZenyaku Kogyo Co., Ltd. · completed · Neoplasms · principal investigator
- Ph1NCT01011972 · A Study of Intravenous XMT-1107 in Patients With Advanced Solid TumorsMersana Therapeutics · completed · Neoplasm Metastasis · principal investigator
- Ph1NCT00724100 · A Trial of ALB 109564(a) in Subjects With Advanced Solid TumorsAlbany Molecular Research, Inc. · terminated · Cancer · principal investigator
- Ph1NCT00524524 · An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid TumorsArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · completed · Advanced Solid Tumors · principal investigator
- Ph1NCT00007917 · Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid TumorsNational Cancer Institute (NCI) · completed · Unspecified Adult Solid Tumor, Protocol Specific · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:32 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- U01CA062490RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00007917
- Administrative CoreP30CA006516 · NCI · DANA-FARBER CANCER INST · PI Deborah J Goff · fiscal years 2018 to 2026Named on NCT00007917
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.